Literature DB >> 16906549

Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.

Patricia Z Page1, Grier P Page, Emmanuel Ecosse, Bruce R Korf, Alain Leplege, Pierre Wolkenstein.   

Abstract

Neurofibromatosis 1 (NF1), a genetic condition most commonly characterized by the presence of dermal neurofibromas and café au lait macules, has a significant impact on Quality of Life (QoL). There is a wide range of phenotypic variability, so that affected individuals may have either medically devastating or relatively mild manifestations that do not impact their daily lives. In this study, the SF-36 and Skindex questionnaires were used to quantitatively investigate the impact of severity and visibility on QoL in an American population. Participants were recruited primarily through advertisements distributed by The Children's Tumor Foundation (CTF). The majority participated by completing a mailed questionnaire in which they rated themselves using Ablon's visibility and Riccardi's severity scales, and then completed the SF-36 and Skindex questionnaires. Participants with NF1 reported a significant impact in all aspects of skin-disease-specific QoL, but the emotional aspect demonstrated the greatest effect. Participants with more visible signs of NF1 reported significantly greater overall effects on their skin-disease-specific QoL than those whose manifestations were more subtle. All domains of general health QoL were affected as well, especially in participants who reported having severe complications. Interestingly, greater visibility was not found to be associated with a significant decrease in general health QoL. These findings are consistent with those found in a French cohort, and demonstrate the utility of incorporating tools designed for use in both the general population and for patients with skin disease in examining the impact of NF1 on QoL.

Entities:  

Mesh:

Year:  2006        PMID: 16906549     DOI: 10.1002/ajmg.a.31422

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  44 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

3.  Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.

Authors:  Pamela L Wolters; Katherine M Burns; Staci Martin; Andrea Baldwin; Eva Dombi; Mary Anne Toledo-Tamula; William N Dudley; Andrea Gillespie; Brigitte C Widemann
Journal:  Am J Med Genet A       Date:  2015-05-14       Impact factor: 2.802

4.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher
Journal:  Neuro Oncol       Date:  2014-10-14       Impact factor: 12.300

5.  Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls.

Authors:  Krister W Fjermestad; Livø Nyhus; Øivind J Kanavin; Arvid Heiberg; Lise B Hoxmark
Journal:  J Genet Couns       Date:  2018-02-10       Impact factor: 2.537

6.  The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.

Authors:  Emily L Zale; Catherine Pierre-Louis; Eric A Macklin; Eric Riklin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2017-12-23       Impact factor: 4.130

7.  Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1.

Authors:  Alanna M Kongkriangkai; Christopher King; Lisa J Martin; Emily Wakefield; Carlos E Prada; Geraldine Kelly-Mancuso; Elizabeth K Schorry
Journal:  Am J Med Genet A       Date:  2019-02-08       Impact factor: 2.802

8.  First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.

Authors:  Christopher J Funes; Ryan A Mace; Erik A Macklin; Scott R Plotkin; Justin T Jordan; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

9.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

Review 10.  Neurofibromatosis type 1.

Authors:  Kevin P Boyd; Bruce R Korf; Amy Theos
Journal:  J Am Acad Dermatol       Date:  2009-07       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.